''GeneCentric...today announced that it will present three posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place in San Diego, California from April 17-22. The company will also participate in the Myriad Genetics Spotlight Theater (“Advances in ctDNA Testing towards Biopharma Development & Clinical Dx”) and Discovery Life Sciences Flash Talk during the meeting.''
"GeneCentric...today announced the launch of its EXpressCTcm (Expression Signatures Through Circulating Tumor Signals) liquid biopsy platform that allows the value of tissue RNA expression and epigenomics to be realized in liquid biopsy. EXpressCT expands the application of the company’s pipeline of RNA-based gene expression signatures and diagnostic tests to cell-free DNA (cfDNA) liquid biopsy samples, including blood and urine."